Reevo S.P.A. (REEVO.MI)
| Chiusura precedente | 13,80 |
| Aperto | 13,80 |
| Denaro | 0,00 x N/D |
| Lettera | 13,80 x N/D |
| Min-Max giorno | 13,80 - 13,80 |
| Intervallo di 52 settimane | 9,72 - 17,90 |
| Volume | |
| Media Volume | 1.886 |
| Capitalizzazione | 69,436M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | 53,08 |
| EPS (ttm) | 0,26 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 17,50 |
- GlobeNewswire
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
– FYARRO™ added to NCCN® Guidelines as the only preferred mTOR inhibitor to treat malignant PEComa –– PRECISION-1 tumor agnostic study for TSC1 or TSC2 alterations is open for enrollment – LOS ANGELES, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the launch and commercial availability of its first proprietary produ
- GlobeNewswire
Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
LOS ANGELES, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. The presentation will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET. The webcas
- GlobeNewswire
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
FYARRO is the first and only approved therapy for adults for the treatment of malignant PEComa, an ultra-rare and aggressive form of sarcoma with a strong female predominanceFYARRO launch planned for Q1 2022; Investor call to be held today at 8:30 am ET LOS ANGELES, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that
